Reliability of tumor primary cultures as a model for drug response prediction: Expression profiles comparison of tissues versus primary cultures from colorectal cancer patients

Journal of Cancer Research and Clinical Oncology

Volumn 138, Issue 3, 2012, Pages 463-482

  Bellot, Gregory Lucien ^a   Tan, Wei Han ^b   Tay, Ling Lee ^a   Koh, Dean ^b   Wang, Xueying ^a,b  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Colorectal cancer; Drug assays; Drug resistance; Microarray; Primary cultures

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AFIMOXIFENE; BICALUTAMIDE; CAPECITABINE; CISPLATIN; CURCUMIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXIFLURIDINE; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; IRINOTECAN; METHOTREXATE; MITOMYCIN; PACLITAXEL; PIRFENIDONE; RALOXIFENE; RESVERATROL; SULINDAC SULFIDE; TOPOTECAN; UFT; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DEOXYCYTIDINE; DRUG DERIVATIVE; FLOXURIDINE; TEGAFUR; URACIL;

ARTICLE; CANCER PATIENT; CLINICAL ARTICLE; COLORECTAL CARCINOMA; CONTROLLED STUDY; DRUG RESPONSE; DRUG SENSITIVITY; EMBRYO; GENE EXPRESSION PROFILING; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; HUMAN TISSUE; INTERMETHOD COMPARISON; MODEL; NUCLEOTIDE SEQUENCE; PREDICTION; PRIORITY JOURNAL; RELIABILITY; TISSUE CULTURE; TUMOR CELL CULTURE; ADENOCARCINOMA; COLORECTAL TUMOR; DOWN REGULATION; DRUG EFFECT; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION; GENETICS; GENOMIC INSTABILITY; METABOLISM; METAPHASE; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE; PROTEIN MICROARRAY; REPRODUCIBILITY; TISSUE MICROARRAY; UPREGULATION;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CISPLATIN; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; DOWN-REGULATION; DOXORUBICIN; ETOPOSIDE; FLOXURIDINE; FLUORESCENT ANTIBODY TECHNIQUE; FLUOROURACIL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOMIC INSTABILITY; HUMANS; METAPHASE; PACLITAXEL; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE OF TESTS; PROTEIN ARRAY ANALYSIS; REPRODUCIBILITY OF RESULTS; TEGAFUR; TISSUE ARRAY ANALYSIS; TUMOR CELLS, CULTURED; UP-REGULATION; URACIL;

EID: 84859751177     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-011-1115-9     Document Type: Article

References (59)

1. Alberts DS, Samon SE, Chen HS, Surwit EA, Soehnlen B, Young L et al (1980) In vitro clonogenic assay for predicting response of ovarian cancer to chemotherapy. Lancet 2(8190):340-342 (Pubitemid 10092662)
2. Arango D, Wilson A, Shi Q, Corner G, Arañes M, Nicholas C et al (2004) Molecular mechanisms of action and prediction of response to oxaliplatin in colorectal cancer cells. Br J Cancer 91(11):1931-1946 (Pubitemid 40065523)
3. Arango D, Laiho P, Kokko A, Alhopuro P, Sammalkorpi H, Salovaara R et al (2005) Gene-expression profiling predicts recurrence in Dukes' C colorectal cancer. Gastroenterology 129(3):874-884 (Pubitemid 41242680)
4. Bainard L, Bainard J, Newmaster S, Klironomos J (2011) Mycorrhizal symbiosis stimulates endoreduplication in angiosperms. Plant Cell Environ 34(9):1577-1585
5. Barrier A, Lemoine A, Boelle P, Tse C, Brault D, Chiappini F et al (2005a) Colon cancer prognosis prediction by gene expression profiling. Oncogene 24(40):6155-6164 (Pubitemid 43080065)
6. Barrier A, Boelle PY, Lemoine A, Tse C, Brault D, Chiappini F et al (2005b) Gene expression profiling of nonneoplastic mucosa may predict clinical outcome of colon cancer patients. Dis Colon Rectum 48(12):2238-2248 (Pubitemid 43074444)
7. Barrier A, Boelle PY, Roser F, Gregg J, Tse C, Brault D et al (2006) Stage II colon cancer prognosis prediction by tumor gene expression profiling. J Clin Oncol 24(29):4685-4691 (Pubitemid 46630932)
8. Barrier A, Roser F, Boëlle PY, Franc B, Tse C, Brault D et al (2007) Prognosis of stage II colon cancer by non-neoplastic mucosa gene expression profiling. Oncogene 26(18):2642-2648 (Pubitemid 46632008)
9. Bass AJ, Watanabe H, Mermel CH, Yu S, Perner S, Verhaak RG et al (2009) SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet 41(11):1238-1242
10. Bazan V, Agnese V, Corsale S, Calò V, Valerio MR, Latteri MA et al (2005) Specific TP53 and/or Ki-ras mutations as independent predictors of clinical outcome in sporadic colorectal adenocarcinomas: results of a 5-year Gruppo Oncologico dell'Italia Meridionale (GOIM) prospective study. Ann Oncol 16(Suppl 4):iv50-iv55 (Pubitemid 43084946)
11. Brouquet A, Taleb P, Lot AS, Beauchet A, Julie C, Prevost G et al (2011) A model of primary culture of colorectal cancer and liver metastasis to predict chemosensitivity. J Surg Res 166(2):247-254
12. Burgering BMT (2008) A brief introduction to FOXOlogy. Oncogene 27(16):2258-2262 (Pubitemid 351501787)
13. Cardoso J, Boer J, Morreau H, Fodde R (2007) Expression and genomic profiling of colorectal cancer. Biochim Biophys Acta 1775(1):103-137 (Pubitemid 44881195)
14. Chen J, Aronow B, Jegga A (2009a) Disease candidate gene identification and prioritization using protein interaction networks. BMC Bioinformatics 10:73
15. Chen J, Bardes EE, Aronow BJ, Jegga AG (2009b) Topp Gene Suite for gene list enrichment analysis and candidate gene prioritization. Nucleic Acids Res 37(Web Server issue):W305-W311
16. Chin L, Hahn WC, Getz G, Meyerson M (2011) Making sense of cancer genomic data. Genes Dev 25(6):534-555
17. Collins FS, Green ED, Guttmacher AE, US National Human Genome Research Institute (2003) A vision for the future of genomics research. Nature 422(6934):835-847 (Pubitemid 36520032)
18. Cree IA, Glaysher S, Harvey AL (2010) EYcacy of anti-cancer agents in cell lines versus human primary tumour tissue. Curr Opin Pharmacol 10(4):375-379
19. Davis AP, King BL, Mockus S, Murphy CG, Saraceni-Richards C, Rosenstein M et al (2011) The comparative toxicogenomics database: update 2011. Nucleic Acids Res 39(Database issue): D1067-D1072
20. Del R, Molina F, Bascoul-Mollevi C, Copois V, Bibeau F, Chalbos P et al (2007) Gene expression signature in advanced colorectal cancer patients select drugs and response for the use of leucovorin, Xuorouracil, and irinotecan. J Clin Oncol 25(7):773-780 (Pubitemid 350002876)
21. Eschrich S, Yang I, Bloom G, Kwong KY, Boulware D, Cantor A et al (2005) Molecular staging for survival prediction of colorectal cancer patients. J Clin Oncol 23(15):3526-3535
22. Fernando A, Glaysher S, Conroy M, Pekalski M, Smith J, Knight LA et al (2006) EVect of culture conditions on the chemosensitivity of ovarian cancer cell lines. Anticancer Drugs 17(8):913-919 (Pubitemid 44350610)
23. Fruehauf J, Alberts D (2003) Assay-assisted treatment selection for women with breast or ovarian cancer. Recent Results Cancer Res 161:126-145
24. Fruehauf JP, Alberts DS (2005) In vitro drug resistance versus chemosensitivity: two sides of different coins. J Clin Oncol 23(15): 3641-3643 author reply 3646
25. Fu Z, Tindall DJ (2008) FOXOs, cancer and regulation of apoptosis. Oncogene 27(16):2312-2319 (Pubitemid 351501782)
26. Gillet JP, Gottesman MM (2010) Mechanisms of multidrug resistance in cancer. Methods Mol Biol 596:47-76
27. Jeppesen P (2000) Immunofluorescence in cytogenetic analysis: method and applications. Genet Mol Bio 23:1003-1014
28. Khambata-Ford S, Garrett C, Meropol N, Basik M, Harbison C, Wu S et al (2007) Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 25(22): 3230-3237 (Pubitemid 47325606)
29. Kulendran M, Stebbing JF, Marks CG, Rockall TA (2011) Predictive and prognostic factors in colorectal cancer: a personalized approach. Cancers 3(2):1622-1638
30. La Farina M, Maturi N, Stira S, Russo A, Bazan V, Albanese I et al (1998) Direct identification of each specific mutation in codon 12 and 13 of ci-ki-ras2 by SSCP analysis. Biochem Biophys Res Commun 246(3):813-815 (Pubitemid 28420940)
31. Lander ES (1996) The new genomics: global views of biology. Science 274(5287):536-539 (Pubitemid 26360427)
32. Lee J, Lee I, Han B, Park J, Jang J, Park C et al (2011) EVect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations. J Natl Cancer Inst 103(8):674-688
33. Lippert TH, Ruoff HJ, Volm M (2011) Current status of methods to assess cancer drug resistance. Int J Med Sci 8(3):245-253
34. Loizzi V, Chan JK, Osann K, Cappuccini F, Di Saia PJ, Berman ML et al (2003) Survival outcomes in patients with recurrent ovarian cancer who were treated with chemoresistance assay-guided chemotherapy. Am J Obstet Gynecol 189(5):1301-1307 (Pubitemid 37542162)
35. Luca T, Privitera G, Lo Monaco M, Prezzavento C, Castorina S (2007) Validation study of a cell culture model of colorectal cancer. Ital J Anat Embryol 112(2):81-92
36. Mariadason J, Arango D, Shi Q, Wilson A, Corner G, Nicholas C et al (2003) Gene expression profiling-based prediction of response of colon carcinoma cells to 5-Xuorouracil and camptothecin. Cancer Res 63(24):8791-8812 (Pubitemid 38064059)
37. Marrinucci D, Bethel K, Lazar D, Fisher J, Huynh E, Clark P et al (2010) Cytomorphology of circulating colorectal tumor cells:a small case series. J Oncol 2010:861341
38. Miyaki M, Seki M, Okamoto M, Yamanaka A, Maeda Y, Tanaka K et al (1990) Genetic changes and histopathological types in colorectal tumors from patients with familial adenomatous polyposis. Cancer Res 50(22):7166-7173
39. Miyaki M, Tanaka K, Kikuchi-Yanoshita R, Muraoka M, Konishi M (1995) Familial polyposis: recent advances. Crit Rev Oncol Hematol 19(1):1-31
40. Moyer A, Sun Z, Batzler A, Li L, Schaid D, Yang P et al (2010) Glutathione pathway genetic polymorphisms and lung cancer survival after platinum-based chemotherapy. Cancer Epidemiol Biomarkers Prev 19(3):811-821
41. Muleris M, Salmon R, Dutrillaux B (1990) Cytogenetics of colorectal adenocarcinomas. Cancer Genet Cytogenet 46(2):143-156
42. Mullighan CG, Goorha S, Radtke I, Miller CB, Coustan-Smith E, Dalton JD et al (2007) Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature 446(7137):758-764 (Pubitemid 46582031)
43. Mullighan CG, Miller CB, Radtke I, Phillips LA, Dalton J, Ma J et al (2008) BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature 453(7191):110-114 (Pubitemid 351630327)
44. Nannini M, Pantaleo MA, Maleddu A, AstolW A, Formica S, Biasco G et al (2009) Gene expression profiling in colorectal cancer using microarray technologies: results and perspectives. Cancer Treat Rev 35(3):201-209
45. Okumura K, Mekata E, Shiomi H, Naitoh H, Abe H, Endo Y et al (2008) Expression level of thymidylate synthase mRNA reflects 5-Xuorouracil sensitivity with low dose and long duration in primary colorectal cancer. Cancer Chemother Pharmacol 61(4):587-594
46. Penland SK, Goldberg RM (2004) Current strategies in previously untreated advanced colorectal cancer. Oncology (Williston Park) 18(6):715-722 727, discussion 727
47. Pezo R, Gandhi S, Shirley L, Pestell R, Augenlicht L, Singer R et al (2008) Single-cell transcription site activation predicts chemotherapy response in human colorectal tumors. Cancer Res 68(13):4977-4982
48. Puig P, Guilly M, Bouchot A, Droin N, Cathelin D, Bouyer F et al (2008) Tumor cells can escape DNA-damaging cisplatin through DNA endoreduplication and reversible polyploidy. Cell Biol Int 32(9):1031-1043
49. Saeed AI, Sharov V, White J, Li J, Liang W, Bhagabati N et al (2003) TM4: a free, open-source system for microarray data management and analysis. Biotechniques 34(2):374-378 (Pubitemid 36184095)
50. Schrag D, Garewal HS, Burstein HJ, Samson DJ, Von Hoff DD, Somerfield MR et al (2004) American society of clinical oncology technology assessment: chemotherapy sensitivity and resistance assays. J Clin Oncol 22(17):3631-3638 (Pubitemid 41103670)
51. Schwerer MJ, Hemmer J, Kraft K, Maier H, Möller P, Barth TFE et al (2003) Endoreduplication in conjunction with tumor progression in an aneuploid laryngeal squamous cell carcinoma. Virchows Arch 443(1):98-103 (Pubitemid 36920957)
52. Shimizu D, Ishikawa T, Ichikawa Y, Togo S, Hayasizaki Y, Okazaki Y et al (2005) Prediction of chemosensitivity of colorectal cancer to 5-Xuorouracil by gene expression profiling with cDNA microarrays. Int J Oncol 27(2):371-376
53. Stein WD, Litman T, Fojo T, Bates SE (2004) A serial analysis of gene expression (SAGE) database analysis of chemosensitivity: comparing solid tumors with cell lines and comparing solid tumors from different tissue origins. Cancer Res 64(8):2805-2816 (Pubitemid 38500619)
54. Szakács G, Gottesman MM (2004) Comparing solid tumors with cell lines: implications for identifying drug resistance genes in cancer. Mol Interv 4(6):323-325 (Pubitemid 40124379)
55. Varesco L, Gismondi V, James R, Robertson M, Grammatico P, Groden J et al (1993) Identification of APC gene mutations in Italian adenomatous polyposis coli patients by PCR-SSCP analysis. Am J Hum Genet 52(2):280-285 (Pubitemid 23072410)
56. Weir BA, Woo MS, Getz G, Perner S, Ding L, Beroukhim R et al (2007) Characterizing the cancer genome in lung adenocarcinoma. Nature 450(7171):893-898 (Pubitemid 350231325)
57. Weitz J, Koch M, Debus J, Höhler T, Galle PR, Büchler MW et al (2005) Colorectal cancer. Lancet 365(9454):153-165 (Pubitemid 40091806)
58. Williams B, Bateman J, Novikov N, Wu C (2007) Disruption of topoisomerase II perturbs pairing in drosophila cell culture. Genetics 177(1):31-46 (Pubitemid 47555829)
59. Wilson M, Brosens J, Schwenen H, Lam E (2011) FOXO and FOXM1 in cancer: the FOXO-FOXM1 axis shapes the outcome of cancer chemotherapy. Curr Drug Targets 12(9):1256-1266